PUKPF

PRUDENTIAL PLC

OTC · Life Insurance · Inc. X0 · CIK 0001116578
$11.85 0.00%
Vol
SEC Reports20

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

20 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 20 neutral. Avg impact: 2.3/10.
NEUTRAL 6-K 2/10
Prudential plc filed a Form 6-K disclosing that Chair of the Board Douglas Flint acquired 12,000 ord
Jun 9, 2026
NEUTRAL 6-K 2/10
Prudential PLC filed a routine 6-K disclosing the repurchase of 1,992,162 ordinary shares over five
Jun 8, 2026
NEUTRAL 6-K 2/10
Prudential plc granted 203,181 new ordinary shares at nil cost to non-employee insurance agents unde
Jun 5, 2026
NEUTRAL 6-K 2/10
Prudential filed a 6-K reporting a grant of 419,318 new ordinary shares to CEO Anil Wadhwani under t
Jun 5, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a Form 6-K reporting routine PDMR transactions for CEO Anil Wadhwani: vesting o
Jun 4, 2026
NEUTRAL 6-K 2/10
Prudential PLC disclosed routine share repurchases executed from May 26-29, 2026, totaling 2,504,266
Jun 1, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a routine 6-K disclosing its total voting rights and issued share capital as of
May 29, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a 6-K reporting the results of its Annual General Meeting held on 28 May 2026,
May 28, 2026
NEUTRAL 6-K 4/10
Prudential PLC filed its 2026 Annual General Meeting resolutions on Form 6-K, renewing routine autho
May 28, 2026
NEUTRAL 6-K 2/10
Prudential plc reported the results of its Annual General Meeting held on 28 May 2026. All 23 resolu
May 28, 2026
NEUTRAL 6-K 2/10
This 6-K filing reports routine dividend reinvestment plan acquisitions by seven PDMRs (including th
May 27, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a 6-K disclosing the repurchase of 1,645,807 ordinary shares over five trading
May 26, 2026
NEUTRAL 6-K 6/10
Prudential plc announces agreement to acquire a 75% controlling stake in Bharti Life Insurance Compa
May 18, 2026
NEUTRAL 6-K 2/10
CEO Anil Wadhwani acquired 3,406 ordinary shares at HKD 121.20 each on May 15, 2026, as dividend acc
May 18, 2026
NEUTRAL 6-K 2/10
Prudential PLC disclosed weekly share repurchases of ~1.28M shares (May 11-15, 2026) under its ongoi
May 18, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a 6-K reporting the admission of 5,728,624 new ordinary shares to trading on th
May 15, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a 6-K announcing the admission of 5,721,904 ordinary shares to trading on the L
May 12, 2026
NEUTRAL 6-K 2/10
Prudential plc filed a 6-K announcing an application to admit 5,721,904 new ordinary shares to tradi
May 12, 2026
NEUTRAL 6-K 2/10
Prudential PLC disclosed a share repurchase of 257,332 ordinary shares at an average price of £11.49
May 11, 2026
NEUTRAL 6-K 2/10
Prudential plc disclosed a routine share buyback transaction on May 7, 2026, repurchasing 252,594 or
May 8, 2026

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution: 91% buy across 23 analysts — 7 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2026-12-31
$0.00 $0.00 $0.00 $18.4B 121.7%
Next FY
2027-12-31
$0.00 $0.00 $0.00 $20.5B 11.3%

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202671420091%
May 1, 202681410096%
Apr 1, 202681510096%
Mar 1, 202681510096%
Feb 1, 202681510096%
Jan 1, 202681410096%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.